ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DBV DBV Technologies

1.304
0.064 (5.16%)
16 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
DBV Technologies EU:DBV Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.064 5.16% 1.304 1.256 1.35 1.48 1.25 1.256 314,082 16:40:00

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

16/01/2024 9:30pm

GlobeNewswire Inc.


DBV Technologies (EU:DBV)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more DBV Technologies Charts.

AMF Regulated InformationMontrouge, France, January 16, 2024

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with NATIXIS ODDO BHF.

Under the liquidity contract between DBV Technologies and NATIXIS ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2023:

  • 222,988 DBV Technologies shares,
  • € 150,264.71.

When the liquidity contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account:

  • 41,159 DBV Technologies shares,
  • € 432,367.25.

Over the period from July 1, 2023, to December 31, 2023, the following transactions were executed:

  • 1,355 buy transactions,
  • 998 sales transactions.

Over this same period, the volumes traded represented:

  • 376,978 shares and € 911,734.76 on purchases,
  • 303,962 shares and € 744,017.58 on sales.

About DBV Technologies

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Attachment

  • PDF Version

1 Year DBV Technologies Chart

1 Year DBV Technologies Chart

1 Month DBV Technologies Chart

1 Month DBV Technologies Chart

Your Recent History

Delayed Upgrade Clock